<DOC>
	<DOCNO>NCT03085017</DOCNO>
	<brief_summary>A prospective randomize open-label study evaluate effectiveness pliable absorbable bone hemostat ( BoneSeal® ) reduction bleed sternal bone marrow patient undergo cardiothoracic surgery .</brief_summary>
	<brief_title>Effectiveness BoneSeal® Bone Hemostats Patients Undergoing Cardiothoracic Surgery</brief_title>
	<detailed_description>A prospective randomize open-label study evaluate effectiveness pliable absorbable bone hemostat ( BoneSeal® ) compose synthetic material hydroxyapatite reduction bleed sternal bone marrow patient undergoing Coronary Artery Bypass Grafting , without valve replacement repair . This product compare similar , currently use product , Ostene® . Bleeding evaluate qualitatively surgeon well quantitatively compare pre- post-operative hemoglobin level , intra-operative post-operative blood product usage , post-operative chest tube output . A 30 day follow-up conducted evaluate patient 's tolerance product , possible complication , infection . Additionally , surgeon ask comment ease use product .</detailed_description>
	<criteria>1 . Consent give patient prior surgery 2 . Adult patient 45 year 3 . Subjects require elective , prescheduled urgent open heart surgery require sternotomy include , limited CABG , valve repair , valve replacement 1 . An immune system disorder 2 . Known hypersensitivity component BoneSeal® Ostene® 3 . Patients undergo emergency surgery 4 . Patients undergoing aortic dissection 5 . No consent give</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>